Code
01SC7325
Duration
01 October 2025 → 30 September 2028
Funding
Regional and community funding: Special Research Fund
Promotor
Research disciplines
-
Medical and health sciences
- Nuclear imaging
Keywords
SSTR2
macrophages
Immune checkpoint inhibitors
tumor microenvironment
personalized treatment
Project description
This research project investigates the predictive value of somatostatin subtype 2 receptor (SSTR-2)
expression in melanoma, triple-negative breast cancer, and renal cell carcinoma for immune
checkpoint inhibitor responses. Through immunohistochemical analysis and 68Ga-DOTATATE
PET/CT imaging, the study aims to correlate SSTR-2 expression with clinical outcomes, enhancing
personalized treatment strategies for these malignancies.